Skip to main content

Betrixaban Pregnancy and Breastfeeding Warnings

Betrixaban is also known as: Bevyxxa

Betrixaban Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: Not assigned

-Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery.
-Consider the risks of bleeding and stroke in using this drug in pregnancy.

Animal studies showed no embryofetal or teratogenic effects at up to 44 times the human dose, however at the highest doses fetal deaths were seen due to maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Betrixaban Breastfeeding Warnings

The manufacturer makes no recommendation regarding use during lactation.

Excreted into human milk: Data not available
Excreted into animal milk: Data not available

-Consider the benefits of breastfeeding along with potential adverse effects on the infant and the underlying maternal condition.

See references

References for pregnancy information

  1. "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals (2017):

References for breastfeeding information

  1. "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals (2017):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.